Second Quarter 2012 Financial Results Conference Call
August 2, 2012
Second Quarter 2012 Financial Results Conference Call August 2, - - PowerPoint PPT Presentation
Second Quarter 2012 Financial Results Conference Call August 2, 2012 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to,
August 2, 2012
1
Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding our gross margin improvement initiatives, the effectiveness of such initiatives and our ability to achieve such improvements, the closure and consolidation of certain of our plants and the cost and timing thereof, closing of pending transactions, the expected impact of currency rates, and financial guidance for 2012, including expected revenues, cash EPS and adjusted cash flow from operations. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “targets,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date
circumstances after the date of this presentation or to reflect actual outcomes. Non-GAAP Information
To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & pp&e step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, acquisition- related and other costs, acquired in-process research and development ("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization and other non-cash charges, amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on assets held for sale/impairment, net, (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company’s core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP. Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.
Note 1: The guidance in this presentation is only effective as of the date given, August 2, 2012, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance.
2
3
Q2 2012 Q2 2011 Q2 2012 vs 2011 Product Sales $749 M $530 M 41% Total Revenue (w/o
$775 M $569 M 36% Cash EPS $1.01 $0.73 38% Cash EPS (w/o one- time items) $0.87 $0.54 61%
4
Q1 2011 Q2 2011 Q3 2011 Q4 2011 Total 2011
GAAP Cash Flow from Operations $86.3 M $190.7 M $173.7 M $189.8 M $640.5 M Adjusted Cash Flow from Operations $203.6 M $259.5 M $208.4 M $253.1 M $924.6 M
Q1 2012 Q2 2012 YTD 2012
GAAP Cash Flow from Operations $167.2 M $254.6 M $421.8 M Adjusted Cash Flow from Operations $321.6 M $307.5 M $629.1 M
5
Same Store Sales* Q2 U.S. Derm 33% U.S. Neuro
Canada / Australia 4% Emerging Markets 12% Total 6% Pro Forma* Q2 U.S. Derm 29% U.S. Neuro
Canada / Australia 2% Emerging Markets 16% Total 10%
* Adjusts for the impact of the impact from foreign exchange, acquisitions and divestitures/discontinuations
6
Same Store Sales* Q1 Q2 LTM 2012 Product Sales 5% 6% 8% 2011 Product Sales 6% 3% n/a 2012 Product Sales
16% 15% 19%
* Adjusts for the impact of the impact from foreign exchange, acquisitions and divestitures/discontinuations
Pro Forma* Q1 Q2 LTM 2012 Product Sales 10% 10% 11% 2012 Product Sales
18% 17% 19%
7
Multiple Plant Consolidations
Improve plant capacity utilization
Negotiate / renegotiate with third party contractors
Move to third party manufacturing where appropriate
Reposition representation business
Preference is to license or own products
De-emphasize partnered product business
Legacy Biovail contracts up for renewal
8
Country Objectives
Brazil Consolidate 3 plants into 1 Australia Shut down owned manufacturing facility, transfer to 3PC’s Mexico Consolidate 5 plants into 2 CEE Consolidate 4 plants into 3 Canada Consolidate 3 Rx plants into 2 Puerto Rico Shut down legacy Valeant plant - move to 3rd Party Mfg / VRX Canadian plants
Action Items and Status
Incremental Cap Ex spend expected to be $50-$60m next 18 months
9
$46 $27 $14 $4
2009* 2010* 2011 2012 - 1H
Ongoing Non-Deal External Legal Spend
Case Settled Entity
Abbott (Fenofibrate) Biovail AWP (Multiple Products) Biovail Cambridge Labs (Xenazine) Biovail Eli Lilly (Permax) Valeant Gradient (Malicious Prosecution) Biovail High Crane (Xenazine) Biovail Mylan (Wellbutrin Canada) Biovail Paddock (Aplenzin) Biovail Par (Aplenzin) Biovail S.A.C. (Malicious Prosecution) Biovail Sandoz (Section 8 Damages) Biovail Wellbutrin XL Class Action Biovail
*Pro forma for legacy companies (millions)
10
Filed NDA for IDP-108 (efinaconazole)
NDA submitted July 2012
Filed Citizen’s Petition for acyclovir ointment (Zovirax)
CP filed July 2012
Potiga U.S. Launch progressing
Recent trends positive
Acquisitions Update
Atlantis (closed) Swiss Herbal (closed) University Medical (closed) OraPharma (closed) Pedinol (closed) Natur Produkts (close by YE) 2 additional deals
Vita Direct – OTC products in Poland Russian diabetes products from BC Pharma
12
Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012 Product Sales $530M $570M $654M $758M $749M Ongoing Service/Alliance Revenue $39 M $31M $34M $32M $26 M Total Revenue excl. “one-timers” $569M $601M $688M $790M $775M One-time items $40 M N/A N/A $66 M $45 M Total Revenue $609M $601M $688M $856M $820M Cost of Goods Sold% (% of product sales) 29% 28% 25% *25% 24% SG&A% (% of total revenue) 22% 21% 20% 19% 22% R&D Expense $18M $18M $17M $22M $18M Operating Margin (% of total revenue) (excluding amortization) 53% 50% 57% 55% 52% Cash EPS (Reported) $0.73 $0.66 $0.94 $1.14 $1.01 w/o one-time items $0.54 $0.66 $0.87 $0.91 $0.87 Adjusted Cash Flow from Operations $260M $208M $253M $322M $307M Fully Diluted Share Count 331 M 323 M 317 M 316 M 313 M
* Q1 2012 COGS has been restated to show impact of contract mfg moved to Service/Alliance (previously stated at 26%)
13
Q1 10 Q2 10 Q3 10 Q4 10 Q1 11 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 Reported Revenues ($M) $452 $494 $467 $515 $565 $609 $601 $688 $856 $820 Sale Cloderm/5FU/IDP111
Milestones
Revenue excl. one-time items ($M) $452 $494 $467 $515 $529 $569 $601 $688 $790 $775 Revenue Growth (vs Prior Year) 17% 15% 28% 34% 49% 36% Reported Cash EPS $0.44 $0.46 $0.40 $0.50 $0.62 $0.73 $0.66 $0.93 $1.14 $1.01 Sale Cloderm/5FU/IDP111 (margin)
Milestones
Gain on Cephalon Shares
One-time Fx Gains
Cash EPS excl. one-time items $0.44 $0.46 $0.40 $0.50 $0.56 $0.54 $0.66 $0.87 $0.91 $0.87 Cash EPS Growth (vs Prior Year) 28% 17% 65% 75% 61% 61% Base Business Cash Earnings ($M) $146 $153 $131 $164 $188 $179 $212 $277 $287 $314 Cash Earnings / Revenue 32% 31% 28% 32% 36% 31% 35% 40% 36% 41% Cash Earnings / Revenue (LTM) 31% 32% 32% 31% 32% 32% 34%
14
$330 $307 $504 $172 $497 $14 $48 $16 $395
Cash March 2012 Securities Repurchases Acquisitions Cap Ex Restructuring/ Integration/ Legal Settlements Other* Cash June 2012 Net Issuance LT Debt Adjusted CashFlow from Operations
* Includes payment of withholding tax upon vesting of share based awards, effect of exchange rate changes on cash balances,
proceeds from the exercise of stock options and other miscellaneous cash outflows
(millions)
15
Acquisition, Integration, & Restructuring Costs: $48.3M in Q2’12 vs $87.3M in Q1’12
Project Type Amount Paid Manufacturing Integration (Various Deals) 10,601 Europe (PharmaSw iss, Sanitas, Gerot Lannach) 5,981 iNova 5,255 Dermik 5,076 Pele Nova 4,483 Ortho 3,318 Eyetech 2,865 OraPharma 2,110 Afexa 1,902 Pedinol 1,815 Intellectual Property Migration 1,099 Other (Atlantis, Probiotica, University Medical, Sw iss Herbal) 3,746 Total 48,250 $ Expense Type Amount Paid Acquisition Related Costs Paid to 3rd Parties 16,122 Severance Payments 13,477 Integration related consulting, duplicative labor, transition services, and other costs 11,513 Facility Closure Costs 2,123 Non-personnel Manufacturing Integration costs 1,904 Other costs 3,111 Total 48,250 $
(000’s)
16
“Year over Year Declining Rates”
0%
AUD BRL CAD EUR MXN PLN RUB RSD ZAR
18
Revenue $3.1 - $3.4 billion
$4.45 - $4.70 Cash EPS*
$4.08 – 4.33 ex one-
time items
> $1.4 billion in Adjusted Cash Flow from Operations
Revenue > $3.4 - 3.6 billion
$4.55 - $4.75 Cash EPS
$4.18 – 4.38 ex one- time items
> $1.4 billion in Adjusted Cash Flow from Operations
See Note 1 regarding guidance
* Re-affirmed at upper end on June 21, 2012
August 2, 2012